Aduhelm Shockwaves Will Reverberate Across Industry
Executive Summary
The butterfly effect is an elegant analogy to describe the seemingly unpredictable and far-reaching implications of a relatively small and inconsequential event. The FDA’s approval of Aduhelm is not so much a butterfly gently flapping its wings, but rather a sonic boom emanating from a jet engine. Most immediately, it provides a new therapeutic option for millions of patients in dire need of hope, vindicating Biogen’s faith with a revenue stream running into many billions of dollars. Longer-term the reverberations may be felt across the entire industry, throwing into question the evidentiary requirement for drug development.
You may also be interested in...
Exec Chat: Cognetivity’s Simple Brain Test Could Unlock Trillions In Health Care Savings
Cognetivity Neuroscience’s CognICA tool uses a language and education-independent approach to assess whether a patient is exhibiting cognitive decline, so it could also aid drug discovery.
Medicare, Alzheimer’s Drugs And The Single Payer Effect
US biopharma stakeholders are getting a taste of how a single payer health care system can shape the fate of a new treatment with Medicare’s national coverage determination for amyloid-directed Alzheimer’s drugs including Biogen/Eisai’s Aduhelm.
Are Biotech Investors Still Being Led By Science Fundamentals?
From the Aduhelm approval to exuberant stock markets, life sciences investor and In Vivo Rising Leader John Cassidy shares insights into industry trends, highlighting areas where decisions may have moved away from scientific fundamentals.